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ABSTRACT  
   
Progestogens, such as progesterone (P4), medroxyprogesterone acetate (MPA), 
and micronized progesterone (mP4), are given to ovary-intact women during the 
transition to menopause to attenuate heavy uterine bleeding and other symptoms. Both 
progesterone and MPA administration have been shown to impair cognition in 
ovariectomized (Ovx) rats compared to vehicle-treated controls. mP4, however, has yet to 
be investigated for cognitive effects in a preclinical setting. Further, progestogens affect 
the GABA (-aminobutyric acid) ergic system, specifically glutamic acid decarboxylase 
(GAD) the rate limiting enzyme necessary for synthesizing GABA. The goal of this 
experiment was to investigate the cognitive impact of P4, MPA, and mP4, in an ovary-
intact transitional menopause model using 4-vinylcyclohexene diepoxide (VCD) and 
assess whether these potential changes were related to the GABAergic system. One group 
of rats received vehicle injections, and the remainder of the groups received VCD to 
induce follicular depletion, modeling transitional menopause in women. Vehicle or 
hormone administration began during perimenopause to model the time period when 
women often take progestogens alone. Rats then underwent testing to assess spatial 
working and reference memory in the water radial-arm maze (WRAM) and spatial 
reference memory in the Morris water maze (MWM). Results indicate that P4 and MPA 
improved learning for working memory measure, but only MPA impaired memory 
retention in the WRAM. For the WRAM reference memory measure, VCD only treated 
rats showed impaired learning and memory retention compared to vehicle controls; 
progestogens did not impact this impairment. Although GAD expression did not differ 
between treatment groups, in general, there was a relationship between GAD expression 
  ii 
and WRAM performance such that rats that tended to have higher GAD levels also 
tended to make more WRAM working memory errors. Thus, while P4 and MPA have 
been previously shown to impair cognition in an Ovx model, giving these hormones early 
in an ovary-intact perimenopause model elicits divergent effects, such that these 
progestogens can improve cognition. Additionally, these findings suggest that the 
cognitive changes seen herein are related to the interaction between progestogens and the 
GABAergic system. Further investigation into progestogens is warranted to fully 
understand their impact on cognition given the importance of utilizing progestogens in 
the clinic. 
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INTRODUCTION 
Menopause occurs at the average age of 52, and is clinically defined as one year 
of missed periods (NAMS, 2015). The transition to menopause involves the 
dysregulation of ovarian hormones as ovarian follicle reserves become deplete. This 
process is not an abrupt phenomenon; indeed, the transition to menopause can last as long 
as 10 years (Burger, Hale, Dennerstein, & Robertson, 2008; Harlow & Paramsothy, 
2011). During menopause, women can undergo a variety of physical changes that result 
in unwanted symptoms, including hot flashes, vaginal dryness, sleep disturbances, as well 
as cognitive changes (NAMS, 2017). In order to combat these undesired effects, hormone 
therapy containing an estrogen component can be prescribed, which have been utilized 
for decades to relieve the unwelcome effects of menopause. Unopposed estrogen 
administration for a woman that has an intact uterus, however, is not advisable as 
estrogens can increase the risk for endometrial hyperplasia and cancer (NAMS, 2012). In 
order to attenuate this risk, progestogens, known as both the endogenous progesterone 
and its synthetic analogs, known as progestins, are prescribed along with estrogens for a 
combination hormone therapy. 
One avenue of research pertinent to understanding women’s health during aging 
concerns hormone therapy and the transition to menopause. During this perimenopausal 
time period, progestogens can be administered to combat heavy uterine bleeding as well 
as other symptoms. Endogenously derived progesterone is not often prescribed clinically 
via the oral route as it has a low oral bioavailability (Kincl, Ciaccio, & Benagiano, 1978). 
Synthetic progestins that are more bioavailable than natural progesterone have been 
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produced for oral administration. We aimed to investigate the effects of different 
progestogens on cognition in a preclinical transitional model of menopause in the rat. 
Type of Progestogen Administered for Neuroprotection and Cognition 
Progesterone, the endogenous circulating hormone found in women, has been 
methodically assessed in preclinical models for effects on the brain and cognition. 
Progesterone has long been known to be neuroprotective in counteracting damage due to 
ischemic stroke and traumatic brain injury in animal models (Shear, Galani, Hoffman, & 
Stein, 2002; Wali, Ishrat, Won, Stein, & Sayeed, 2014). Indeed, progesterone and its 
metabolites, such as allopregnanolone, have various neuroprotective effects. For 
example, allopregnanolone and 5-dihydroprogesterone, another metabolite of 
progesterone,  reduced neuronal loss induced via kainic acid excitotoxicity in 
hippocampal rat neurons (Ciriza, Azcoitia, & Garcia-Segura, 2004). In adult male rats 
with injury to the prefrontal cortex, vehicle-treated controls demonstrated cell loss at the 
injury site that was attenuated by progesterone or allopregnanolone treatments (Djebaili 
et al., 2004). Further, progesterone- or allopregnanolone- treated rats had improved 
spatial reference memory as assessed on the MWM compared to the vehicle-treated rats 
with injury at the prefrontal cortex. Progesterone- or allopregnanlone- treated rats did not, 
however, differ in spatial reference memory from the non-injured vehicle-treated 
controls, indicating that the neuroprotective effects of progesterone and allopregnanolone 
on spatial reference memory were limited to injured rats (Djebaili et al., 2004).  
Although there is evidence suggesting that progesterone can be neuroprotective, 
there is also preclinical research suggesting that progesterone administration can have 
mixed effects on cognition in healthy animals. Variances in outcomes have been shown 
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to stem from differences in study design such as dose of progesterone, duration of 
administration, route of administration, cognitive assays assessed, and preclinical model 
utilized. Some research has suggested that progesterone administration can be beneficial 
for cognition. For example, in the ovariectomy model (Ovx), where the ovaries have been 
surgically removed, treatment with a single bolus of a medium (10 mg/kg) or a high dose 
(20 mg/kg) of progesterone in young Ovx mice improved performance on an object 
recognition task, a non-spatial task, compared to vehicle controls (Harburger, Pechenino, 
Saadi, & Frick, 2008). Similarly, in middle-aged and aged Ovx mice, acute progesterone 
treatment improved memory consolidation in a dose dependent manner during an object 
recognition task (Lewis, Orr, & Frick, 2008). Additionally, an acute high dose of 
progesterone (20 mg/kg) improved spatial reference memory on the Morris Water Maze 
(MWM) task for the aged Ovx mice but not for the middle-aged Ovx mice, indicating 
that age at treatment plays a role in the potential beneficial cognitive effects of 
progesterone (Lewis et al., 2008). In contrast, our laboratory has demonstrated that 
chronic progesterone administration (0.7 mg/day) given to middle-aged Ovx rats impairs 
spatial working memory (Braden et al., 2015). Further, chronic progesterone (200 mg 
sustained release over 60 days via pellet) given in combination with 17-estradiol (the 
most potent, endogenous, circulating estrogen in mammals) attenuated the beneficial 
effects of 17-estradiol alone on spatial reference memory as assessed by the MWM task 
(H. A. Bimonte-Nelson, Francis, Umphlet, & Granholm, 2006). Of note, the differences 
in cognitive functioning between these studies could be due to other differences in study 
design such as the fact that the acute progestogen treatments were given to mice instead 
of rats. Further, acute treatments of progesterone were administered at a higher dose than 
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those in the chronic conditions which could have differentially influenced performance 
on cognitive tasks. These data indicate that a myriad of factors could influence the impact 
of progestogen treatment on cognitive outcomes. 
Synthetic progestins are separated into two distinct classes based on chemical 
structure, those that resemble progesterone, and those that resemble testosterone and as 
such they can have differential methods of action in the brain and peripheral tissues 
(Stanczyk, 2003). The progesterone-like progestins can be further categorized into 
pregnane derivatives and 19 norpregnane derivatives. One such progestin of interest is 
medroxyprogesterone acetate (MPA) an acetylated pregnane derivative (Stanczyk, 2003). 
Currently, perimenopausal women are often administered MPA to alleviate undesired 
physiological symptoms, such as heavy uterine bleeding; MPA is also available in the 
clinic as a common form of birth control (brand name DepoProvera) (Depo Provera 
Prescribing Information, 2006). Although progestogens can have beneficial effects on the 
uterus to reduce heavy bleeding, their effects on cognition can be varied and should be 
carefully considered during clinical administration. The Women’s Health Initiative 
Memory Study (WHIMS) called into question the effectiveness of hormone therapy for 
cognition and for effects on dementia risk in menopausal women 65 years old and over. 
Data from the WHIMS indicate that postmenopausal women administered conjugated 
equine estrogens (CEE) with MPA as a combination hormone therapy had an increased 
risk of dementia that was clinically meaningful as well as a doubled risk of dementia 
compared to controls (Rapp et al., 2003; Shumaker et al., 2003). MPA alone has been 
shown by our and other laboratories to have negative effects on cognition in the rat 
(Braden et al., 2017; Okojie & Oyekunle, 2014). Specifically, MPA has been shown to 
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have impairing effects on spatial memory in Ovx rats compared to sham controls (Braden 
et al., 2017, 2011, 2010). It is possible that this cognitive impairment of MPA is non-
reversible as rats tested four months after the cessation of MPA treatment (which 
occurred for four months) still demonstrated cognitive impairment compared to age 
matched vehicle controls (Braden, Garcia, Mennenga, Lazlo, et al., 2011). Furthermore, 
in vitro MPA treatment has not demonstrated neuroprotection against glutamate-induced 
excitotoxicity, and when combined with 17-estradiol, MPA attenuated the 
neuroprotective effects of 17-estradiol alone (Nilsen & Brinton, 2002). These findings 
demonstrate the potential for MPA to impair cognition, as well as brain functioning, in 
both clinical and preclinical populations. 
Women can also be administered micronized progesterone (brand name 
Prometrium) to combat physiological symptoms associated with perimenopause, 
specifically endometrial hyperplasia and secondary amenorrhea (Prometrium Prescribing 
Information). Secondary amenorrhea is the cessation of menstruation for three or more 
months without concurrent pregnancy, birth control regimen, or menopause transition. 
Micronized progesterone is the more orally active form of progesterone and is 
synthesized from yams (De Lignières, 1999; Maxson & Hargrove, 1985). Micronization 
reduces particle size, increasing the relative surface area and solubility of the particle 
thereby making it more orally bioavailable (Chakmakjian & Zachariah, 1987; Hargrove, 
Maxson, & Wentz, 1989; Maxson & Hargrove, 1985; Williams et al., 2013). Micronized 
progesterone is identical in chemical structure to progesterone, yet smaller in particle size 
and presumably acts upon the same neurobiological pathways as progesterone. 
Micronized progesterone has multiple clinical applications; it is prescribed to prevent 
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preterm labor and subsequent birth (Choudhary, Suneja, Vaid, Guleria, & Faridi, 2014; 
Glover et al., 2011; Rai et al., 2009) and has recently been investigated for its potential 
alleviation of symptoms associated with polycystic ovarian syndrome and cocaine abuse  
although results have been varied (Livadas et al., 2010; Reed, Evans, Bedi, Rubin, & 
Foltin, 2011). Previous research investigating the effect of MPA and micronized 
progesterone in combination with conjugated equine estrogens (CEE) in non-
hysterectomized, postmenopausal women found that women given micronized 
progesterone and CEE showed improved quality of life perception over a nine-month 
period since the beginning of treatment (Ryan & Rosner, 2001). Recently, an ancillary 
study of the Kronos Early Estrogen Prevention Study (KEEPS), the Cognitive and 
Affective Study (KEEPS-Cog), investigated the effects of micronized progesterone in 
combination with CEE or 17ß-estradiol, in ovary-intact women who underwent the 
natural transition to menopause (Gleason et al., 2015; Miller et al., 2009). No cognitive 
effects were found, however, with any of the hormone regimens tested (Gleason et al., 
2015). This is contradicted by another study which found better performance in working 
memory as well as improved delayed verbal memory in menopausal women administered 
CEE with micronized progesterone when compared to their scores before taking this 
hormone combination therapy (Sherwin & Grigorova, 2011). To date, there has been no 
research conducted on the effects of micronized progesterone on cognition in a rodent 
model. It stands to reason that micronized progesterone, with its higher oral 
bioavailability, might exacerbate effects on cognition and should be investigated. 
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Transitional Model of Menopause 
Preclinical menopause-related progestogen investigations have been limited thus 
far to models of surgical menopause via Ovx. Ovx models surgical menopause in animals 
by abruptly removing the primary source for ovarian hormones, resulting in a drastic 
decrease in circulating ovarian hormone levels. However, the majority of women in the 
U.S. do not generally undergo surgical menopause. Indeed, roughly 600,000 women a 
year undergo hysterectomy, the surgical removal of the uterus, half of which occur with 
concurrent oophorectomy, the surgical removal of the ovaries in women (Whiteman et 
al., 2008). Instead of surgical menopause, most women undergo a form of naturally 
occurring menopause during which the finite follicular ovarian pool depletes via 
accelerated atresia which results in a transition to menopause rather than an abrupt loss of 
ovaries (NAMS, 2015). The Ovx model provides a blank circulating ovarian-derived 
hormone profile which makes it an ideal model to assess gonadal hormone deprivation 
and exogenous hormone administration in rodents. The natural transition to menopause, 
however, is much more complicated and also requires systematic evaluation. 
A newer rodent model of menopause has been created that can be utilized to 
address the cognitive effects of hormones in a translationally relevant transitional form of 
menopause. By administering 4-vinylcyclohexene diepoxide (VCD), a metabolite of 4-
vinylcyclohexene, researchers can induce ovarian follicular depletion of primary and 
primordial follicles via accelerated atresia that more closely models a woman’s natural 
menopause transition (Hoyer, Devine, Xiaoming, Thompson, & Sipes, 2001; Kao, Sipes, 
& Hoyer, 1999; Springer, Flaws, Sipes, & Hoyer, 1996). The VCD model not only more 
accurately reflects the transitional form of menopause compared to the Ovx model, by 
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inducing follicular depletion, but also produces a circulating ovarian hormone profile 
which is more similar to a woman undergoing transitional menopause compared to the 
Ovx model. Specifically, the intact VCD-treated ovaries produce less progesterone while 
androgen levels, most predominantly androstenedione, decrease at a much slower rate, 
creating an androgen-rich hormone milieu (Acosta et al., 2010; Koebele et al., 2017; 
Mayer, Devine, Dyer, & Hoyer, 2004). These physiological differences between the Ovx 
and the VCD model, perhaps, lead to distinct behavioral differences between the two 
models when hormone therapy is additionally administered. For instance, one study 
found that compared to vehicle in middle-aged controls, CEE administration in middle-
aged Ovx rats enhanced cognition while CEE given to middle-aged rats with VCD-
induced follicular depletion impaired cognition compared to vehicle controls. These 
results indicate that transitionally menopausal VCD-treated rats yielding a high androgen, 
low estrogen, and low progesterone environment respond differently to CEE than Ovx 
rats with a hormonal environment that is void of endogenous, circulating ovarian 
hormones (Acosta et al., 2010). Moreover, a negative correlation was found between 
androstenedione levels in the VCD-treated rats and memory performance on a spatial 
working and reference memory task (Acosta et al., 2010). It is possible that the 
androstenedione-dominant milieu in the VCD model could lead to cognitive impairment 
and thus, the two models could have opposing effects of CEE. Further research suggests 
that it is the conversion of androstenedione to estrone that underlies the impairment in 
cognition with transitional menopause (Mennenga, Koebele, et al., 2015). Specifically, 
our laboratory found that when the activity of the aromatase enzyme, which synthesizes 
androstenedione to estrone, was blocked, there was a reversal of spatial working and 
  9 
reference memory impairments induced by androstenedione in young Ovx rats 
(Mennenga, Koebele, et al., 2015). There was no reversal of these androstenedione-
induced memory deficits when the androgen receptor was blocked, indicating that the 
androstenedione-induced impairments were due its conversion to estrone rather than its 
activity at the androgen receptor (Mennenga, Koebele, et al., 2015). Another difference 
between the VCD model compared to the Ovx model is that the VCD model allows for 
targeted timing of the menopause transition. Ovx is an all or nothing abrupt phenomenon, 
while follicular depletion with VCD occurs over time. As such, with the VCD model, 
hormones can be administered during the transition to menopause and scientists can now 
target perimenopausal time points as avenues of research which had been difficult to 
investigate prior to this model as the Ovx model lacks a transition stage. There are 
caveats, however, to the VCD model. VCD is a caustic chemical used in the creation of 
epoxy and rubber tires (Chhabra, 1989) and recent research has revealed that VCD might 
lead to oxidative stress and heightened inflammatory factors in young-adult female rats 
(Abolaji et al., 2016). Assessing exogenous progestogen administration in the VCD 
model of follicular depletion will further our understanding of hormone interactions 
given during the perimenopausal transition. 
Progestogens and the GABAergic System 
Progesterone and MPA have long been implicated in affecting the GABA (-
aminobutyric acid) ergic system. GABA is the most potent endogenous inhibitory 
neurotransmitter found in the central nervous system (CNS) (Sieghart & Sperk, 2002).  
The primary function of the GABAergic system is to inhibit neuronal activity. As such, 
effects of GABA are primarily anxiolytic and anesthetic in nature. GABA most 
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commonly acts through the GABAA receptor, and several metabolites of progesterone 
have a high affinity for the GABAA receptor and are considered positive allosteric 
modulators (Paul & Purdy, 1992). Our laboratory has previously reported that 
progesterone and MPA treatment can impact the GABAergic system by influencing 
glutamic acid decarboxylase (GAD), the rate limiting enzyme necessary for synthesizing 
GABA. Specifically, progesterone and MPA treatment significantly increased GAD 
65+67 levels in the entorhinal cortex, and decreased GAD 65+67 levels in the dorsal 
hippocampus, in aged Ovx female rats, although this effect was tempered for 
progesterone with a marginal effect for this hormone (Braden et al., 2010). Further, 
higher levels of serum MPA correlated with decreased expression of GAD 65+67 in the 
dorsal hippocampus in rats treated with MPA throughout their adult lifespan (Braden, 
Garcia, Mennenga, Prokai, et al., 2011). MPA has also been shown to increase inhibitory 
tone in the dentate gyrus (Belelli & Herd, 2003). Additionally, administering bicuculline, 
a GABAA receptor antagonist to progesterone-treated middle-aged Ovx rats, attenuated 
the memory impairments seen in progesterone only-treated rats indicating a role for the 
GABAergic system in modulating the effects of progesterone on cognition (Braden et al., 
2015). As all of these studies have been conducted in the Ovx model, it is necessary to 
evaluate whether these findings are similar in an ovary-intact model, such as with the 
VCD model of follicular depletion, to assess if variants in menopause type can affect 
cognitive outcomes with progestogen treatment. Indeed, utilizing the Ovx model does not 
allow for evaluation of hormones given during the transition to menopause, as the Ovx 
model yields an abrupt cessation of endogenous circulating ovarian hormones. 
Understanding the role of progestogens on the GABAergic system when given during the 
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transition to menopause will better our understanding of one potential mechanism of the 
change in cognitive performance associated with progestogen based hormone therapy. 
Research Aims and Hypotheses 
This study aimed to investigate the effects of three different progestogens, MPA, 
micronized progesterone, and progesterone, administered alone (without estrogen) in an 
ovary-intact transitional model of menopause, on spatial working and reference memory 
as well as the GABAergic system in the rat. Progesterone was added as a treatment group 
to directly compare the effects of micronization on the two bioidentical hormones. We 
hypothesized that MPA and progesterone would impair cognition, as has been shown in 
numerous Ovx rodent studies (Braden et al., 2010, 2011, 2015, 2017). We also 
hypothesized that micronized progesterone would have impairing effects on cognition, as 
it the micronized form of the naturally occurring progesterone (De Lignières, 1999; 
Maxson & Hargrove, 1985). Neither MPA nor micronized progesterone have been 
investigated in a transitional rodent model of menopause. 
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MATERIALS AND METHODS 
Subjects 
49 six month-old, female, virgin, Fischer-344-CDF rats were obtained from the 
National Institute on Aging (NIA). Animals were pair-housed and fed ad libitum for two 
weeks before hormone administration began which continued until the end of the study. 
Animals were placed on a 12-hour on/off light-dark cycle, and were treated in 
compliance with the Arizona State University IACUC protocol. 
VCD Administration 
Rats were administered either VCD (160mg/kg/day, in 47% dimethyl sulfoxide 
(DMSO)/saline vehicle, 6% VCD, n=39) (SenesTech Inc., Flagstaff, AZ) or vehicle 
solution (47% DMSO/saline, n=10) (Sigma-Aldritch, St. Louis, MO) via intraperitoneal 
(i.p.) injection in accordance with past research and published protocols (Acosta et al., 
2009, 2010; Flaws, Doerr, Sipes, & Hoyer, 1994; Koebele et al., 2017; Springer et al., 
1996). VCD injections began two weeks after arrival and occurred four times a week 
(every Monday, Tuesday, Thursday, Friday) for six weeks. One animal died during VCD 
injections due to a medical condition not related to VCD treatment. The first day of VCD 
injections was considered day 1 of the study; the rest of the timeline will be referred to as 
days from first injection of VCD. 
Progestogen Administration 
Daily subcutaneous injections began on day 52 (from the start of VCD injections). 
Day 52 was chosen as the beginning point for progestogen injections as previous research 
had indicated that at 52 days from the beginning of VCD injections, progesterone levels 
were similar to vehicle controls for young or middle-aged rats administered VCD 
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(Koebele et al., 2017). Rats received either progesterone (P4) (0.7mg/rat/day in 0.3 ml 
sesame oil, n=10), micronized progesterone (mP4) (0.7mg/rat/day in 0.3 ml sesame oil, 
n=9), medroxyprogesterone acetate (MPA) (0.7mg/rat/day in 0.3 ml sesame oil, n=10), or 
vehicle (0.3 ml sesame oil, n=20). Rats were separated by treatment groups such that all 
progestogens were administered to rats who had received VCD injections (VCD-P4, 
VCD-mP4, VCD-MPA). Two groups were given sesame oil vehicle injections (VCD-
Vehicle, Vehicle-Vehicle) and were used as controls for this study. The doses of MPA 
and P4 used herein have been shown by our laboratory to impair spatial working memory 
(Braden et al., 2015, 2017). The dose for mP4 was chosen to match that of the P4 dose so 
direct comparisons could be made. Daily injections continued until sacrifice at day 132. 
See Fig. 1 for study timeline. 
Vaginal Smears 
Vaginal smears occurred for 10 consecutive days two weeks before behavioral 
testing began. Smears were determined to be metestrus, diestrus, proestrus or estrus as 
indicated in a previous protocol (Goldman, Murr, & I, 2007). 
Water Radial Arm Maze (WRAM) 
Rats began behavioral testing 111 days after receiving the first injection of VCD, 
and 59 days after the start of vehicle or hormone injections. The WRAM was used to 
assess spatial memory, specifically working and reference memory paradigms. The maze 
consisted of eight arms radiating outwardly from a circular center. Each arm was 38.1cm 
x 12.7cm. Robust visual cues were placed on the walls adjacent to the maze such that 
they could be seen by the rats. The maze contained water that was kept at 18-20C and 
non-toxic black paint was used to create an opaque surface that the animals could not see 
  14 
below. Four of the eight arms contained hidden platforms (10 cm diameter) 2 cm below 
the surface of the water. These platforms were kept in consistent locations at the 
beginning of each testing day for each rat but were semi-randomized between rats. All 
location patterns used were balanced across the maze such that no quadrant of the maze 
was underrepresented. 
Rats were tested for 12 consecutive days, with four trials each day. The start arm 
remained constant for all rats and trials. At the start of the first trial, rats were taken out of 
their cage and placed in the start arm. Rats were allowed to swim freely in the maze until 
they found a platform or until 3 minutes had elapsed after which rats were led to the 
closest platform. After rats found a platform they were allowed to stay there for 15 
seconds and then they were removed and placed in their warm testing cage for an inter-
trial interval (ITI) of 30 seconds. During this ITI, the just-found platform was removed 
and the maze was cleaned to remove debris and distribute olfactory cues. After the ITI, 
rats were again placed in the start arm and allowed to follow the same protocol as the first 
trial. This continued until the end of the fourth trial after which animals were returned to 
their testing cage for the rest of the day. Performance was assessed via three separate 
error types: working memory correct (WMC) errors, reference memory (RM) errors, and 
working memory incorrect (WMI) errors. WMC errors were defined as an entry into an 
arm which previously contained a platform for that day. RM errors were defined as the 
first entry into an arm which never contained a platform. WMI errors were defined as all 
subsequent entries, other than the first, into an arm that never contained a platform. As 
the trials increased, working memory load increased since rats had to keep more items in 
  15 
their working memory. On the last day of testing a six-hour delay was implemented 
between trial 2 and trial 3 to assess delayed memory retention in these rats. 
Morris Water Maze (MWM) 
The MWM is a water escape task that is used to assess spatial reference memory. 
The maze was a circular pool that was 188 cm in diameter. The water was kept at 18-
20C and non-toxic black paint was used to create an opaque surface. A platform (10 cm 
diameter) was hidden 2 cm below the surface of the water in the north-east quadrant of 
the maze. Robust visual cues were situated on adjacent walls to aid spatial navigation. A 
camera was mounted above the maze and the computer program Ethovision 10 (Noldus 
Instruments) was used to capture video and track the rat’s path through the maze. 
Distance to platform (cm) from the drop-off point was recorded and used to assess spatial 
localization of the platform over a time period of five days. 
Rats were tested for five consecutive days, with four trials each day. At the start 
of the first trial, animals were dropped off at one of four drop off points (North, South, 
East or West) that were semi-randomly assigned to each trial throughout each of the days. 
Once in the maze, rats were allowed to swim freely until they found the platform or until 
one minute had elapsed after which rats were then led to the platform. Rats were allowed 
to stay on the platform for 15 seconds, after which time the rat was returned to their 
testing cage for a 5-8 minute ITI. On Day 5, the last day of testing, after all test trials, a 
probe trial was introduced to assess whether the animals had spatially localized the 
position of the platform. Before the probe trial began the platform was removed and rats 
were allowed to swim freely in the maze for one minute after which they were returned to 
their testing cages. 
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Visible Platform 
The visible platform test was used to assess motor and visual acuity for solving a 
water escape task. The maze was a rectangular pool (39 X 23 cm) filled with clear water 
kept at 18-20C. The maze was encircled by a curtain so that there were no salient visual 
cues other than those found inside the maze. There was a platform situated inside the 
maze (10 cm diameter) protruding two cm above the water. 
Rats were tested for one day with six trials. At the start of trial 1, animals were 
placed in the starting position that remained constant throughout trials. The rats were 
allowed to swim freely until they found the platform. After the rats found the platform 
they were allowed to stay on it for 15 seconds after which the tester returned rats to their 
testing cage for an ITI of 5-8 minutes. All rats were tested for trial 1 before moving on to 
trial 2. Platform locations were assigned semi-randomly across trials. Latency to the 
platform was measured. 
Sacrifice 
Rats were sacrificed over two days, at the end of behavioral testing. Final body 
weights (g) were obtained earlier in the day directly before daily injections on the first 
day of sacrifices. Rats were anesthetized via isoflurane, and cardiocentesis was 
performed for blood collection. Rats were then decapitated and brains removed for 
dissection. Seventeen separate brain regions were raw brain dissected (left and right 
cingulate gyrus, left and right frontal cortex, basal forebrain, left and right striatum, left 
and right dorsal hippocampus, left and right perirhinal cortex, left and right entorhinal 
cortex, left and right temporal association area, and left and right CA1/CA2 region of the 
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hippocampus) directly after removal. Tissue was weighed immediately afterwards, frozen 
and stored at -70C until further analysis. 
Uterine horn and ovarian weights, and intestinal removal 
Uterine horns and ovaries were dissected out of the body cavity and trimmed of 
excess fat. Ovaries were cut from the tips of the uterine horns and separately weighed as 
left and right wet weights (g). Ovaries were then placed in 10% formalin for two days, 
and then switched to 70% ethanol until future analysis. Uterine horn wet weights (g) were 
also collected. Intestines were also removed, trimmed of fat, and flash frozen and stored 
at -70C for further analysis. 
Western Blot 
GAD 65 and GAD 67 expression levels were assessed from the right hemisphere 
in the frontal cortex, dorsal hippocampus, basal forebrain, ventral hippocampus, 
perirhinal cortex and entorhinal cortex via Western Blot analysis. Samples were 
homogenized via probe sonicator (Ultrasonic Processor, Cole Parmer, IL, USA) in a 1:50 
RIPA buffer (1% Triton X-100, 150mM NaCl, 0.5% Na Deoxycholate, 0.1% SDS, 
50mM Tris, phosphatase inhibitor [Cat#: 524625, Millipore-Sigma], and protease 
inhibitor [Cat#: 5892791001, Millipore-Sigma]). Samples were then centrifuged at 
10,000 rpm for 10 minutes at 4C. A BCA (bicinchoninic acid) protein assay 
(ThermoFisher Scientific) was utilized to measure protein concentration. Samples were 
run on a 4-12% Bis-Tris NuPAGE gel using a SureLock Mini-Cell system (Invitrogen, 
Carlsbad, CA, USA) and transferred to a polyvinylidene difluoride membrane 
(Immobulin-P). Samples were loaded at 10g of protein per brain region. Treatment 
groups were counterbalanced across gels and four gels were run per brain region. After 
  18 
transfer the membrane was blocked in 5% milk for one hour after which it was incubated 
overnight in primary antibodies anti-GAD 65 (1:5000, Abcam) and anti-GAD 67 
(1:10,000, Abcam) as well as primary antibody anti-beta actin (1:20,000, Cell Signaling) 
as a control measure. The membrane was then incubated in secondary antibodies anti-
mouse horseradish peroxidase (1:2000, Cell Signaling) and anti-rabbit horseradish 
peroxidase (1:2000, Cell Signaling) for one hour. Chemoluminescence (LumiGlo and 
Peroxide, Cell Signaling) was used to visualize protein expression using a film developer. 
ImageJ software was used to perform densitometry. GAD 65+67 levels were normalized 
to Vehicle-Vehicle samples for analysis. 
Statistical Analyses 
WRAM data were analyzed across days 2-12 using an omnibus repeated measures 
analysis of variance (ANOVA) for each of the memory types (WMC, WMI, and RM 
errors). The repeated measures were Trials nested within Days while the independent 
variable was Treatment. Data were further separated into three distinct blocks for Days 2-
5 (the learning phase), Days 6-9, and Days 10-12 (the asymptotic phase) and each block 
was individually assessed via an omnibus repeated measures ANOVA for each of the 
error types. Effects of treatment on Day 12 alone were also assessed as previous research 
in our laboratory has shown impairments after MPA administration in Ovx rats on the last 
day of WRAM testing (Braden et al. 2017, 2010). Additionally, we compared 
performance amongst groups for the highest (Trial 4) working memory load as our 
laboratory has previously shown that effects of several hormone-altering treatments 
become apparent when working memory load is highly taxed (Bimonte & Denenberg, 
1999; Braden et al., 2010; Koebele et al., 2017). For the delay, for each treatment group 
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separately, baseline trials from day 12, trials 3 and 4, were averaged and compared to the 
averaged postdelay trials from day 13, trials 3 and 4, as has been previously reported 
(Camp et al., 2012; Engler-Chiurazzi et al., 2011; Mennenga, Gerson, et al., 2015; 
Mennenga, Koebele, et al., 2015; Prakapenka et al., 2018). 
MWM total swim distance data were analyzed using an omnibus repeated 
measures ANOVA for all days of testing. The repeated measures were Trials nested with 
Days, and the independent variable was Treatment. Additionally, the probe trial was 
analyzed by assessing percent distance swim distance in the target quadrant (NE 
quadrant) where the platform had been previously located and in the opposite quadrant 
(SE quadrant) in order to determine if the rats had correctly spatially localized the 
platform location. 
Visible platform data were assessed using a repeated measures ANOVA where 
time to platform was the dependent variable. The repeated measure was Trials and the 
independent variable was Treatment. 
Uterine horn data were assessed using an omnibus ANOVA where wet weight (g) 
adjusted to final body weight (g) was the dependent variable and Treatment was the 
independent variable. 
One way ANOVAs were utilized to assess GAD 65+67 protein levels in the 
frontal cortex, dorsal hippocampus, basal forebrain, ventral hippocampus, perirhinal 
cortex, and entorhinal cortex. GAD 65+67 levels were normalized to the Vehicle-Vehicle 
treatment data. The independent variable was Treatment. To further assess the 
relationship between GAD expression and cognition, Pearson r correlations were 
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analyzed for GAD 65+67 in each brain region for WMC and WMI errors for all blocks of 
WRAM data. 
RESULTS 
WRAM 
The omnibus ANOVA for Days 2-12, including all trials, revealed a main effect 
of Day for WMC, WMI, RM, and Total errors [WMC, F(10, 880) = 6.283, p < 0.001; 
WMI, F(10, 1320) = 24.652, p < 0.001; RM, F(10, 1320) = 12.430, p < 0.001; Total, 
F(10, 1290) = 15.238, p < 0.001], indicating that all animals learned the task across Days 
2-12. There was also a main effect of Trial for Days 2-12 for all days for WMC, WMI, 
RM, and Total errors [WMC, F(2, 880) = 610.278, p < 0.001; WMI F(3, 1320) = 
154.272, p < 0.001; RM F(3, 1320) = 25.594, p < 0.001; Total, F(3, 1290) = 249.703, p < 
0.001], indicating that as trials progressed errors increased and performance deteriorated. 
For Days 2-5, there was a main effect of Treatment for WMI errors [F(4, 396) = 
2.740, p < .05] as well as RM errors [F(4, 396) = 3.393, p = < 0.05] (See Fig. 2 & 3). 
Fischer post-hoc analyses revealed that for WMI errors, VCD only-treated rats made 
more errors than Vehicle-treated rats [p < 0.05], and that MPA- and P4- treated rats made 
fewer errors than VCD only-treated rats [VCD-Vehicle vs. VCD-MPA, p < 0.001, VCD-
Vehicle vs. VCD-P4, p < 0.05], indicating that MPA and P4 treatment attenuated the 
impairment in working memory seen with VCD treatment alone. For RM errors, Fischer 
post-hoc analyses revealed that mP4-, P4-, and VCD only- treated rats each made more 
errors than Vehicle-treated rats [Vehicle-Vehicle vs. VCD-mP4, p < 0.05, Vehicle-
Vehicle vs. VCD-P4, p < 0.05, Vehicle-Vehicle vs. VCD-Vehicle, p < 0.01], indicating 
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an impairment with VCD-induced transitional menopause, an effect not impacted by the 
progestogen treatments. There were no effects of Day, Trial, or Treatment for Days 6-9. 
 For Days 10-12 there was a similar main effect of treatment for RM errors [F(4, 
396) = 2.889, p < 0.05] (See Fig. 4). Fischer post-hoc analyses revealed that all 
progestogen groups as well as VCD only-treated rats made more errors, indicating worse 
performance, than Vehicle-treated rats [Vehicle-Vehicle vs. VCD-mP4, p < 0.05, 
Vehicle-Vehicle vs. VCD-MPA, p < 0.01, Vehicle-Vehicle vs. VCD-P4, p < 0.05, 
Vehicle-Vehicle vs. VCD-Vehicle, p < 0.01]; these results demonstrate an impairment of 
VCD-induced transitional menopause compared to Vehicle-treatment alone that was not 
altered by any of the progestogen treatments. 
For Day 12 only, for all trials, there was a Trial x Treatment interaction for WMI 
errors [F(12, 132) = 8.714, p < 0.05] (See Fig. 5). Analysis of trial 4 alone, the highest 
working memory load trial, revealed a main effect of Treatment [F(4, 44) = 2.638, p < 
0.05]. Fischer post-hoc analyses revealed MPA-treated rats made more errors than all 
other treatment groups on trial 4 during the last day of testing [Vehicle-Vehicle vs. VCD-
MPA, p < 0.01, VCD-Vehicle vs. VCD-MPA, p < 0.05, VCD-P4 vs. VCD-MPA, p < 
0.05, VCD-mP4 vs. VCD-MPA, p < 0.05], indicating an impairment induced by MPA 
administration relative to all other progestogen treatments. 
 For Day 13, after the six-hour delay occurred, there were no main effects of Day 
for any error type between postdelay trials and baseline trials (data not shown) suggesting 
that all groups were able to maintain optimal performance after a six-hour delay period. 
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MWM 
There was a main effect of day for all days of testing such that swim distance 
decreased across days [F(4, 44) = 75.750, p < 0.0001] (See Fig. 6). There was no main 
effect of Treatment nor any significant Treatment x Day interaction indicating that there 
were no differences between treatment groups for learning across days. For the probe 
trial, there was a main effect of Quadrant such that there was a higher percent swim 
distance in the target quadrant (NE quadrant), which had previously contained the 
platform, than the opposite quadrant (SW quadrant), indicating correct spatial localization 
of the platform [F(1, 44) = 361.118, p < 0.0001] (See Fig. 6). There were no Treatment x 
Quadrant interactions, indicating that treatment groups did not differ in their spatial 
localization of the platform. 
Visible Platform 
The visible platform test was used to assess the animals’ ability to perform the 
procedural components of a water escape task. There was a main effect of Trial [F(5, 44) 
= 8.479, p < 0.0001] such that as trials progressed latency to the platform decreased, 
indicating better performance as trials progressed with an average latency of 7.55 seconds 
to reach the platform across all trials (See Fig. 7). There was no main effect of Treatment 
nor a significant Trial x Treatment interaction, indicating that the groups did not differ in 
their ability to perform the procedural components of a water-escape task. 
Uterine Horn Weights 
For uterine horn weights there was a main effect of Treatment when adjusted for 
final body weight [F(4, 44) = 7.811, p < 0.001] (See Fig. 8). Fischer post-hoc analyses 
revealed that the VCD only-treated rats had uterine horns that weighed significantly less 
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than Vehicle-treated rats [p < 0.05]. Additionally, all three progestogens groups had 
uterine horns that weighed significantly less than Vehicle-treated rats [VCD-MPA vs. 
Vehicle-Vehicle, p < 0.01, VCD-P4 vs. Vehicle-Vehicle, p < 0.001, VCD-mP4 vs. 
Vehicle-Vehicle, p < 0.01]. P4-treated rats had uterine horns that weighed significantly 
less than VCD only-treated rats, p < 0.05. 
Western Blot Analysis 
Western blots were performed to assess GAD 65 and 67 protein expression in the 
frontal cortex, dorsal hippocampus, basal forebrain, ventral hippocampus, perirhinal 
cortex and entorhinal cortex. There were no significant effects of treatment for GAD 
65+67 for any region (data not shown). After placing a stringent alpha value of p < 0.01 
to account for multiple correlations, a significant relationship was revealed for cognitive 
performance in the VCD only-treated group as well as for cognitive performance in the 
P4-treated group whereby higher levels of GAD 65+67 were associated with worse 
performance on the WRAM. Specifically, in the perirhinal cortex there was a significant 
correlation between GAD 65+67 expression and Days 2-5 WMI errors for the VCD-
Vehicle group [r(9) = 0.765, p < 0.01, Fig. 9A] suggesting that the VCD only-treated rats 
that tended to have higher GAD 65+67 levels in the perirhinal cortex tended to make 
more WMI errors during the learning phase of WRAM testing. Similarly, in the frontal 
cortex there was a significant correlation between GAD 65+67 expression and Days 10-
12 WMI errors for the VCD-Vehicle group [r(9) = 0.773, p < 0.01, Fig. 9B] suggesting 
that the VCD only-treated rats that tended to have higher GAD 65+67 levels in the frontal 
cortex tended to make more WMI errors during the asymptotic phase of WRAM testing. 
Additionally, in the ventral hippocampus there was a significant correlation between 
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GAD 65+67 expression and Days 2-5 WMC errors for the P4-treated group [r(9) = 0.804, 
p < 0.01, Fig. 9C] suggesting that the P4-treated rats that tended to have higher GAD 
65+67 levels in the ventral hippocampus tended to make more WMC errors during the 
learning phase of WRAM testing. There were no significant correlations for cognitive 
performance and GAD 65+67 expression for any other treatment groups for any brain 
region assessed. 
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DISCUSSION 
The current study is the first to investigate the effects of micronized progesterone, 
the micronized form of natural progesterone, and MPA, a progestin, on cognition in a 
transitional model of menopause. We found that, overall, VCD only-treated animals 
made more errors than Vehicle-treated animals, indicating that follicular depletion 
impaired spatial working and reference memory on the WRAM, replicating recent 
findings from our laboratory (Koebele et al., 2017). We demonstrated that MPA impaired 
spatial working memory relative to vehicle controls on the last day of WRAM testing, 
similar to our prior findings in the rat Ovx model (Braden et al., 2010, 2017). We found 
that VCD only-treated rats exhibited impaired spatial reference memory on the WRAM 
compared to Vehicle-treated rats in both the learning phase and the asymptotic phase, and 
that none of the progestogen treatments impacted this relationship. Interestingly, we 
found beneficial effects of MPA and progesterone on spatial working memory during the 
learning phase of the WRAM. These findings are divergent from previous research in 
Ovx models which demonstrate that MPA and progesterone can impair spatial working  
memory on the WRAM (Braden et al., 2010, 2011, 2015, 2017). We also demonstrated 
that there were no group differences in spatial reference memory on the MWM indicating 
that the effects of progestogen administration are spatial working memory specific. 
Our noted progestogen-induced enhancement could be due, in part, to the fact that 
these hormones were assessed in a follicle deplete, ovary-intact, VCD rat model. With the 
VCD rat model, there is a marked difference in hormonal milieu as compared to Ovx, 
such that there is an androgen-rich hormone profile with VCD treatment, while with the 
Ovx model there is an abrupt cessation of all ovary-derived hormones, including 
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androgens. Higher androgen levels that are present in an ovary-intact model of rodent 
menopause could be interacting with these progestogens to beneficially influence 
acquisition of the WRAM. Additionally, timing of hormone administration could also 
play a role in these beneficial effects. Prior research evaluating hormone therapies in rat 
menopausal models has focused either on the pre-menopausal normally cycling rat, or 
post-menopausal Ovx rat. With the Ovx procedure, the surgical removal of the ovaries 
results in an abrupt cessation of hormones. As such, there is no transitional menopausal 
period during which hormones can be administered. In most VCD studies performed 
previously, hormone administration usually occurred after animals had become fully 
follicle deplete. To our knowledge, no other laboratory has studied the effects of hormone 
administration during the transition to menopause in a follicle depleting model. We have 
shown that by 52 days after the first injection of VCD, middle-aged rats still had 
detectable levels of progesterone that did not differ from vehicle treated rats (Koebele et 
al., 2017). The data collected from Koebele et al (2017) were only a snapshot of hormone 
levels and information about fluctuations in ovarian hormones at this time point were not 
obtained. Administration of progestogens on the background of this perimenopausal 
milieu in the rat could account for the differential impacts to cognition between the VCD 
and Ovx models. 
These findings suggest that there are differential effects of progestogens on spatial 
working and reference memory when administered during the transition to menopause in 
the rat. Specifically, VCD-Vehicle animals showed impaired cognition compared to 
Vehicle-Vehicle animals. MPA attenuated the VCD-induced spatial working memory 
deficit during learning, but impaired compared to all other treatments at the lattermost 
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portion of testing during memory retention. Progesterone also attenuated the VCD-
induced spatial working memory deficit during learning, but had neutral effects during 
memory retention. For the reference memory component of the WRAM, all progestogens 
as well as VCD-Vehicle animals performed worse than Vehicle-Vehicle animals 
indicating that all three progestogens were unable to alleviate the cognitive impairments 
imposed by VCD. These findings suggest that differential impacts of progestogens with 
transitional menopause are dependent upon the type of memory assessed. Spatial working 
and reference memory are inherently different processes. Spatial working memory is a 
form of short term memory that needs to be updated within a session while spatial 
reference memory is form of long term memory that remains constant over time 
(Bimonte-Nelson et al., 2015). As these two memory types are connected yet distinct in 
function, it is understandable that progestogens could have differential effects between 
memory types. 
Progestogens and the GABAergic System 
In general, there was a trend whereby rats that tended to have higher expression of 
GAD 65+67 also tended to make more working memory errors on the WRAM for the 
frontal cortex, perirhinal cortex, and ventral hippocampus. This is consistent with 
previous research indicating that increased activation in the GABAergic system could 
lead to memory impairments (Curran, 1986). Since we found similar trends in 
relationships between memory and several different brain regions, it is probable that the 
effects of progestogen treatment on the GABAergic system are global in nature. 
Additionally, given that progestogen treatment influenced spatial working memory rather 
than spatial reference memory, it is interesting to note that we found correlations between 
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GAD expression and performance on the WRAM specific to brain regions involved in 
working memory processes (e.g. frontal cortex and ventral hippocampus) (D’Esposito & 
Postle, 2015; Kim & Levin, 1996). Also of note, we did not observe group differences for 
performance on the MWM which assesses spatial reference memory, nor did we observe 
significant correlations between GAD expression and performance on the WRAM for the 
dorsal hippocampus, a region of the brain necessary for spatial reference memory (Moser, 
Moser, & Andersen, 1993). Taken together, these data indicate that the spatial working 
memory changes induced by progestogen treatment interact with the GABAergic system 
in a region-specific manner.  
It is also possible that progesterone could be influencing the GABAergic system 
through the progesterone metabolite, allopregnanolone, which has been known to 
positively regulate the effects of GABA on GABAA receptors regardless of subunit type 
(Backstrom et al., 2014). Some research postulates that the cognitive and brain changes 
seen with progesterone treatment are led by its conversion to allopregnanolone via the 
synthesizing enzymes 5-reductase and 3-hydroxysteroid dehydrogenase. Like 
progesterone, allopregnanolone has been investigated for its effects on cognition in 
preclinical models. Some studies suggest that allopregnanolone treatment inhibits spatial 
reference memory on the MWM (Johansson, Birzniece, Lindblad, Olsson, & Bäckström, 
2002; Türkmen, Löfgren, Birzniece, Bäckström, & Johansson, 2006). Additionally, 
partial tolerance to acute allopregnanolone treatment on the MWM was demonstrated and 
researchers posited that chronic exposure of allopregnanolone in women due to menstrual 
cycle, pregnancy, and hormone therapy after menopause might affect cognitive outcomes 
in women that could be mediated by the GABAergic system (Türkmen et al., 2006). 
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MPA has also been known to inhibit metabolites of progesterone via reduction of 3-
hydroxysteroid dehydrogenase, which is necessary for the synthesis of allopregnanolone, 
and to increase inhibitory tone of neurons in the dentate gyrus (Belelli & Herd, 2003). 
Investigation into the interactions between the interplay of these progestogens and the 
GABAergic system will be imperative to understand the mechanism by which these 
progestogens influence cognitive outcomes. 
Further research should be conducted to replicate these findings, as this is the first 
study to investigate the effects of progestogen administration during the transition to 
menopause in a rodent model. Different time points of administration during the 
transition to menopause should also be evaluated to optimize potential beneficial effects 
of each progestogen. In order to begin to understand the potential mechanisms of action 
of progestogen treatment in the brain, additional analysis of brain regions important for 
spatial working memory, such as the frontal cortex, should be systematically assessed in 
the follicle-deplete VCD model given varied hormone therapy preparation. Furthermore, 
micronized progesterone is typically administered via the oral route (De Lignières, 1999; 
Maxson & Hargrove, 1985). As this study administered micronized progesterone via 
subcutaneous injection, future studies should assess oral administration of micronized 
progesterone and other progestogens to model the route of administration utilized by 
women in the clinic. 
Concluding Remarks 
Hormone therapy, in which progestogens play a vital role, has been utilized for 
decades to combat the unwelcome symptoms that occur during the transition to 
menopause. It is crucial to understand the effects that these hormones can have on 
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cognition and the brain to discover the optimal hormone therapy for both peripheral and 
cognitive effects. This study demonstrates that a common hormone therapy component, 
MPA, can have differential effects on spatial working memory depending upon stage of 
learning and memory. The current work also suggests that MPA and progesterone are 
beneficial to cognition in specific circumstances, while prior to this study most work 
identified MPA and progesterone as cognitively-impairing.  Additionally, it is likely that 
these progestogens play a role in the relationship between GABA-mediated signaling and 
cognition. Further research should be conducted utilizing the VCD model to assess 
timing of administration of progestogens, and how progestogens could be interacting with 
the different hormonal profiles as menopause progresses, for impacts on cognition as well 
as the GABAergic system.
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Figure 1.   Study Timeline. 52 days after the first VCD injection, animals began receiving 
daily subcutaneous injections of progestogen or vehicle treatments. 111 days after the 
first injection of VCD animals began behavior testing which consisted of 13 days of 
WRAM, 5 days of MWM, 1 day of visible platform, and 2 days of sacrifices. In total the 
study lasted 132 days since the first injection of VCD. 
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Figure 2. WRAM Days 2-5 WMI errors across treatment groups. Mean error scores 
(+SE) averaged across trials. Main effect of treatment [F(4, 396) = 2.740, p < .05]. The 
MPA- and P4-treated groups performed better than the VCD-Vehicle group [VCD-
Vehicle vs. VCD-MPA, p < .001, VCD-Vehicle vs. VCD-P4, p < .05]. The VCD-Vehicle 
group performed worse than Vehicle-Vehicle group [p < .05]. 
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Figure 3. WRAM Days 2-5 RM errors across treatment groups. Mean error scores (+SE) 
averaged across trials. Main effect of treatment [F(4, 396) = 3.393, p = < 0.05]. All 
progestogen groups, except MPA, as well as the VCD-Vehicle group, performed worse 
than the Vehicle-Vehicle group [Vehicle-Vehicle vs. VCD-mP4, p < 0.05, Vehicle-
Vehicle vs. VCD-P4, p < 0.05, Vehicle-Vehicle vs. VCD-Vehicle, p < 0.01].  
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Figure 4. WRAM Days 10-12 RM errors across treatment groups. Mean error scores 
(+SE) averaged across. Main effect of treatment [F(4, 396) = 2.889, p < 0.05]. All 
progestogen groups as well as VCD-Vehicle performed worse than Vehicle-Vehicle 
[Vehicle-Vehicle vs. VCD-mP4, p < 0.05, Vehicle-Vehicle vs. VCD-MPA, p < 0.01, 
Vehicle-Vehicle vs. VCD-P4, p < 0.05, Vehicle-Vehicle vs. VCD-Vehicle, p < 0.01]. 
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Figure 5. WRAM Day 12 only, WMI errors across treatment groups. Mean error scores 
(+SE) for all treatment groups. There was a significant Trial x Treatment interaction 
[F(12, 132) = 8.714, p < 0.05]. When trial 4 alone was assessed there was a main effect 
of treatment [F(4, 44) = 2.638, p < 0.05]. VCD-MPA treated rats performed worse than 
all other treatment groups on trial 4 [VCD-Vehicle vs. VCD-MPA, p < 0.05, Vehicle-
Vehicle vs. VCD-MPA, p < 0.01, VCD-P4 vs. VCD-MPA, p < 0.05, VCD-mP4 vs. VCD-
MPA, p < 0.05]. 
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Figure 6. MWM. Mean error scores (+SE) for all treatment groups. There was a 
significant effect of Day [F(4, 44) = 75.750, p < 0.0001]. There were no differences 
between treatment groups. When the probe trial was assessed, there was a significant 
effect of quadrant [F(1, 44) = 361.118, p < 0.0001]. Rats had a higher percent swim 
distance in the target NE quadrant compared to the opposite SW quadrant [NE vs. SW, p 
< 0.0001]. 
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Figure 7. Visible Platform Task. Mean error scores (+SE) for all treatment groups. There 
was a significant effect of Trial [F(5, 44) = 8.479, p < 0.0001]. There were no differences 
between treatment groups. 
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Figure 8. Uterine Horn (g) weight adjusted for final body weight. Main effect of 
treatment [F(4, 44) = 7.811, p < 0.001]. All three progestogens groups and the VCD-
Vehicle group had uterine horns that weighed significantly less than Vehicle-Vehicle 
[VCD-Vehicle vs. Vehicle-Vehicle, p < 0.05, VCD-MPA vs. Vehicle-Vehicle, p < 0.001, 
VCD-P4 vs. Vehicle-Vehicle, p < 0.001, VCD-mP4 vs. Vehicle-Vehicle, p < 0.01]. VCD-
P4 had uterine horns that weighed significantly less than VCD-Vehicle, p < .05. 
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Figure 9. Pearson r correlations between WRAM performance and GAD levels for Days 
2-5 and Days 10-12 of testing. (A) GAD 65+67 expression in the perirhinal cortex was 
positively correlated with Days 2-5 WMI errors for the VCD-Vehicle group. (B) GAD 
65+67 expression in the frontal cortex was positively correlated with Days 10-12 WMI 
errors for the VCD-Vehicle group. (C) GAD 65+67 expression in the ventral 
hippocampus was positively correlated with Days 2-5 WMC errors for the VCD-P4 
group. 
 
1 .5 2 .0 2 .5
0
1 0
2 0
3 0
4 0
R  P e r irh in a l G A D  6 5 + 6 7  &  W M I D 2 -5  C o rr
V C D  O n ly
R  P e r irh in a l G A D  6 5 + 6 7
(n o rm a liz e d  to  V e h ic le -V e h ic le )
W
M
I 
D
 2
-5
S
u
m
 o
f 
E
r
r
o
r
s
r = 0.765 
p < 0.01 
1 .8 2 .0 2 .2 2 .4
0
1
2
3
4
5
R  F ro n ta l G A D  6 5 + 6 7  &  W M I D 1 0 -1 2  C o rr
V C D  O n ly
R  F ro n ta l G A D  6 5 + 6 7
(n o rm a liz e d  to  V e h ic le -V e h ic le )
W
M
I 
D
 1
0
-1
2
S
u
m
 o
f 
E
r
r
o
r
s
r = 0.773 
p < 0.01 
1 .0 1 .5 2 .0 2 .5 3 .0
0
1 0
2 0
3 0
4 0
R  V H ip p o  G A D  6 5 + 6 7  &  W M C  D 2 -5  C o rr
P r o g e s te ro n e  O n ly
R  V e n tra l H ip p o  G A D  6 5 + 6 7
(n o rm a liz e d  to  V e h ic le -V e h ic le )
W
M
C
 D
 2
-5
S
u
m
 o
f 
E
r
r
o
r
s
r = 0.804 
p < 0.01 
A 
B 
C 
  40 
REFERENCES 
[Accessed 4 April 2017] Depo Provera Prescribing Information. Pfizer for Professionals. 
2006. Available at 
http://media.pfizer.com/files/products/uspi_depo_provera_contraceptive.pdf 
 
[Accessed 4 April 2017] Prometrium Prescribing Information. Virtus Pharmaceuticals. 
2016. Available at 
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a451784e-f6a0-
414a-8409-3407f1d1d086&type=display 
 
Abolaji, A. O., Adedara, I. A., Abajingin, A. O., Fatunmibi, O. J., Ladipo, E. O., & 
Farombi, E. O. (2016). Evidence of oxidative damage and reproductive dysfunction 
accompanying 4-vinylcyclohexene diepoxide exposure in female Wistar rats. 
Reproductive Toxicology, 66, 10–19. https://doi.org/10.1016/j.reprotox.2016.09.009 
 
Acosta, J. I., Mayer, L. P., Braden, B. B., Nonnenmacher, S., Mennenga, S. E., & 
Bimonte-Nelson, H. A. (2010). The cognitive effects of conjugated equine estrogens 
depend on whether menopause etiology is transitional or surgical. Endocrinology, 
151(8), 3795–3804. https://doi.org/10.1210/en.2010-0055 
 
Acosta, J. I., Mayer, L., Talboom, J. S., Tsang, C. W. S., Smith, C. J., Enders, C. K., & 
Bimonte-Nelson, H. A. (2009). Transitional versus surgical menopause in a rodent 
model: Etiology of ovarian hormone loss impacts memory and the acetylcholine 
system. Endocrinology, 150(9), 4248–4259. https://doi.org/10.1210/en.2008-1802 
 
Backstrom, T., Bixo, M., Johansson, M., Nyberg, S., Ossewaarde, L., Ragagnin, G., … 
van Wingen, G. (2014). Allopregnanolone and mood disorders. Progress in 
Neurobiology, 113, 88–94. 
 
Belelli, D., & Herd, M. B. (2003). The contraceptive agent provera enhances GABAA 
receptor-mediated inhibitory neurotransmission in the rat hippocampus: Evidence 
for endogenous neurosteroids? Journal of Neuroscience, 23(31), 10013–10020. 
 
Bimonte-Nelson, H. A., Francis, K. R., Umphlet, C. D., & Granholm, A. C. (2006). 
Progesterone reverses the spatial memory enhancements initiated by tonic and cyclic 
oestrogen therapy in middle-aged ovariectomized female rats. European Journal of 
Neuroscience, 24(1), 229–242. https://doi.org/10.1111/j.1460-9568.2006.04867.x 
 
Bimonte-Nelson, H., Daniel, J., & Koebele, S. (2015). The mazes. In H. A. Bimonte-
Nelson (Ed.), The Maze Book: Theories, Practice, and Protocols for Testing Rodent 
Cognition (pp. 37–72). NY: Springer Publishing, Human Press. 
 
Bimonte, H. A., & Denenberg, V. H. (1999). Estradiol facilitates performance as working 
memory load increases. Psychoneuroendocrinology, 24(2), 161–173. 
  41 
Braden, B. B., Andrews, M. G., Acosta, J. I., Mennenga, S. E., Lavery, C., & Bimonte-
Nelson, H. A. (2017). A comparison of progestins within three classes: Differential 
effects on learning and memory in the aging surgically menopausal rat. Behavioural 
Brain Research, 322, 258–268. https://doi.org/10.1016/j.bbr.2016.06.053 
 
Braden, B. B., Garcia, A. A., Mennenga, S. E., Lazlo, P., Villa, S. R., Acosta, J. I., … 
Bimonte-Nelson, H. A. (2011). Cognitive-imparing effects of medroxyprogesterone 
acetate in the rat: independent and interacive effect across time. 
Psychopharmacology, 218(2), 405–418. 
https://doi.org/10.1016/j.pestbp.2011.02.012.Investigations 
 
Braden, B. B., Garcia, A. N., Mennenga, S. E., Prokai, L., Villa, S. R., Acosta, J. I., … 
Bimonte-Nelson, H. A. (2011). Cognitive-impairing effects of medroxyprogesterone 
acetate in the rat: independent and interactive effects across time. 
Psychopharmacology, 218(2), 405–418. https://doi.org/10.1038/jid.2014.371 
 
Braden, B. B., Kingston, M. L., Whitton, E., Lavery, C., Tsang, C. W. S., & Bimonte-
Nelson, H. A. (2015). The GABA<inf>A</inf> antagonist bicuculline attenuates 
progesterone-induced memory impairments in middle-aged ovariectomized rats. 
Frontiers in Aging Neuroscience, 7(JUL), 1–8. 
https://doi.org/10.3389/fnagi.2015.00149 
 
Braden, B. B., Talboom, J. S., Crain, I. D., Simard, A. R., Lukas, R. J., Lazlo, P., … 
Bimonte-Nelson, H. A. (2010). Medroxyprogesterone acetate impairs memory and 
alters the GABAergic sytem in aged surgically menopausal rats. Neurobiol Learn 
Mem, 93(3), 444–453. https://doi.org/10.3816/CLM.2009.n.003.Novel 
 
Burger, H. G., Hale, G. E., Dennerstein, L., & Robertson, D. M. (2008). Cycle and 
hormone changes during perimenopause: the key role of ovarian function. 
Menopause (New York, N.Y.), 15(4), 603–612. 
 
Camp, B. W., Gerson, J. E., Tsang, C. W. S., Villa, S. R., Acosta, J. I., Braden, B. B., … 
Bimonte-Nelson, H. A. (2012). High serum androstenodione levels correlate with 
impaired memory in the surgically menopausal rat: a replication and new findings. 
European Journal of Neuroscience, 36(8), 3086–3095. 
https://doi.org/10.1016/j.immuni.2010.12.017.Two-stage 
 
Chakmakjian, Z. H., & Zachariah, N. Y. (1987). Bioavailability of progesterone with 
different modes of administration. Journal of Reproductive Medicine, 32(6), 443–
448. 
 
Choudhary, M., Suneja, A., Vaid, N. B., Guleria, K., & Faridi, M. M. A. (2014). 
Maintenance tocolysis with oral micronized progesterone for prevention of preterm 
birth after arrested preterm labor. International Journal of Gynecology and 
Obstetrics, 126(1), 60–63. 
  42 
 
Ciriza, I., Azcoitia, I., & Garcia-Segura, L. M. (2004). Reduced progesterone metabolites 
protect rat hippocampal neurones from kainic acid excitotoxicity in vivo. Journal of 
Neuroendocrinology, 16(1), 58–63. 
 
Curran, H. V. (1986). Tranquillising memories: A review of the effects of 
benzodiazepines on human memory. Biological Psychology, 23, 179–213. 
 
D’Esposito, M., & Postle, B. (2015). The cognitive neuroscience of working memory. 
Annual Review of Psychology, 66, 115–142. 
 
De Lignières, B. (1999). Oral micronized progesterone. Clinical Therapeutics, 21(1), 41–
60. 
 
Djebaili, M., Hoffman, S. W., & Stein, D. G. (2004). Allopregnanolone and progesterone 
decrease cell death and cognitive deficits after a contusion of the rat pre-frontal 
cortex. Neuroscience, 123, 349–359. 
 
Engler-Chiurazzi, E., Tsang, C. W. S., Nonnenmacher, S., Liang, W. S., Corneveaux, J. 
J., Prokai, L., … Bimonte-Nelson, H. A. (2011). Tonic Premarin Dose-Dependently 
Enchances Memory, Affects Neurotrophin Protein Levels and Alters Gene 
Expression in Middle-Aged Rats. Neurobiol. Aging, 32(4), 680–697. 
https://doi.org/10.1038/jid.2014.371 
 
Flaws, J. A., Doerr, J. K., Sipes, I. G., & Hoyer, P. B. (1994). Destruction of preantral 
follicles in adult rats by 4-vinyl-1-cyclohexene diepoxide. Reproductive Toxicology, 
8(6), 509–514. https://doi.org/10.1016/0890-6238(94)90033-7 
 
Gleason, C. E., Dowling, N. M., Wharton, W., Manson, J. A. E., Miller, V. M., Atwood, 
C. S., … Asthana, S. (2015). Effects of Hormone Therapy on Cognition and Mood 
in Recently Postmenopausal Women: Findings from the Randomized, Controlled 
KEEPS???Cognitive and Affective Study. PLoS Medicine, 12(6), 1–25. 
https://doi.org/10.1371/journal.pmed.1001833 
 
Glover, M. M., McKenna, D. S., Downing, C. M., Smith, D. B., Croom, C. S., & Sonek, 
J. D. (2011). A randomized trial of micronized progesterone for the prevention of 
recurrent preterm birth. American Journal of Perinatology, 28(5), 377–381. 
 
Goldman, J. M., Murr, A. S., & I, C. R. (2007). The roden estrous cycle: characterization 
of vaginal cytology and its utility in toxicological studies. Birth Refects Research 
(Part B), 80, 113–125. 
 
Harburger, L. L., Pechenino, A. S., Saadi, A., & Frick, K. M. (2008). Post-Training 
Progesterone Dose-Dependently Enhances Object, But Not Spatial, Memory  
 
  43 
Consolidation. Behavioural Brain Research, 194(2), 174–180. 
https://doi.org/10.1038/jid.2014.371 
 
Hargrove, J. T., Maxson, W. S., & Wentz, A. C. (1989). Absorption of oral progesterone 
is influenced by vehicle and particle size. American Journal of Obstetrics and 
Gynecology, 161(4), 948–951. 
 
Harlow, S. D., & Paramsothy, P. (2011). Menstruation and the menopausal transition. 
Obstetrics and Gynecology Clinics of North America, 38(3), 595–607. 
 
Hoyer, P. B., Devine, P. J., Xiaoming, X. iaoming H., Thompson, K. E., & Sipes, I. G. 
(2001). Ovarian toxicity of 4 -vinylcyclohexene diepoxide : A mechanistic model, 
29(1), 91–99. 
 
Johansson, I. M., Birzniece, V., Lindblad, C., Olsson, T., & Bäckström, T. (2002). 
Allopregnanolone inhibits learning in the Morris water maze. Brain Research, 934, 
125–131. 
 
Kao, S. W., Sipes, I. G., & Hoyer, P. B. (1999). Early effects of ovotoxicity induced by 
4-vinylcyclohexene diepoxide in rats and mice. Reproductive Toxicology, 13(1), 67–
75. https://doi.org/10.1016/S0890-6238(98)00061-6 
 
Kim, J. S., & Levin, E. D. (1996). Nicotinic, muscarinic and dopaminergic actions in the 
ventral hippocampus and the nucleus accumbens: Effects on spatial working 
memory in rats. Brain Research, 725, 231–240. 
 
Kincl, F. A., Ciaccio, A., & Benagiano, G. (1978). Increasing oral bioavailibility of 
progesterone by formulation. Journal of Steroid Biochemistry, 9, 83–84. 
 
Koebele, S. V., Mennenga, S. E., Hiroi, R., Quihuis, A. M., Hewitt, L. T., Poisson, M. L., 
… Bimonte-Nelson, H. A. (2017). Cognitive changes across the menopause 
transition: A longitudinal evaluation of the impact of age and ovarian status on 
spatial memory. Hormones and Behavior, 87, 96–114. 
https://doi.org/10.1016/j.yhbeh.2016.10.010 
 
Lewis, M. C., Orr, P. T., & Frick, K. M. (2008). Differential effects of acute progesterone 
administration on spatial and object memory in middle-aged and aged female 
C57BL/6 mice. Hormones and Behavior, 54(3), 455–462. 
 
Livadas, S., Boutzios, G., Economou, F., Alexandraki, K., Xyrafis, X., Christou, M., … 
Diamanti-Kandarakis, E. (2010). The effect of oral micronized progesterone on 
hormonal and metabolic parameters in anovulatory patients with polycystic ovary 
syndrome. Fertility and Sterility, 94(1), 242–246. 
 
 
  44 
Maxson, W. S., & Hargrove, J. T. (1985). Bioavailability of oral micronized 
progesterone. Fertility and Sterility, 44(5), 622–626. 
 
Mayer, L. P., Devine, P. J., Dyer, C. A., & Hoyer, P. B. (2004). The follicle-deplete 
mouse ovary produces androgen. Biology of Reproduction, 71, 130–138. 
https://doi.org/10.1095/biolreprod.103.016113 
 
Mennenga, S. E., Gerson, J. E., Koebele, S. V., Kingston, M. L., Tsang, C. W. S., Engler-
Chiurazzi, E., … Bimonte-Nelson, H. A. (2015). Understanding the Cognitive 
Impact of the Contraceptive Estrogen Ethinyl Estradiol: Tonic and Cyclic 
Administration Impairs Memory, and Performance Correlates With Basal Forebrain 
Cholinergic System Integrity. Psychoneuroendocrinology, 54, 1–13. 
https://doi.org/10.1002/aur.1474.Replication 
 
Mennenga, S. E., Koebele, S. V., Mousa, A. A., Alderete, T. J., Tsang, C. W. S., Acosta, 
J. I., … Bimonte-Nelson, H. A. (2015). Pharmacological Blockade of the Aromatase 
Enzyme, But Not the Androgen Receptor, Reverses Androstenedione-Induced 
Cognitive Impairments in Young Surgically Menopausal Rats. Steroids, 99(0), 16–
25. https://doi.org/10.1158/1078-0432.CCR-15-0428.Bioactivity 
 
Miller, V. M., Black, D. M., Brinton, E. A., Budoff, M. J., Cedars, M. I., Hodis, H. N., … 
Harman, S. M. (2009). Using basic science to design a clinical trial: Baseline 
characteristics of women enrolled in the Kronos Early Estrogen Prevention Study 
(KEEPS). Journal of Cardiovascular Translational Research, 2, 228–239. 
 
Moser, E., Moser, M. B., & Andersen, P. (1993). Spatial learning impairment parallels 
the magnitude of dorsal hippocampal lesions, but is hardly present following ventral 
lesions. Journal of Neuroscience, 13(9), 3916–3925. 
 
NAMS. (2012). The 2012 Hormone Therapy Position Statement of The North American 
Menopause Society (NAMS). Menopause: The Journal of The North American 
Menopause Society, 19(3), 257–271. 
https://doi.org/10.1097/gme.0b013e31824b970a 
 
NAMS. (2015). Nonhormonal management of menopause-Associated vasomotor 
symptoms: 2015 position statement of the North American Menopause Society 
(NAMS). Menopause: The Journal of The North American Menopause Society, 
22(11), 1–18. 
 
NAMS. (2017). The 2017 hormone therapy position statement of the North American 
Menopause Society (NAMS). Menopause: The Journal of The North American 
Menopause Society, 24(7), 728–753. 
 
 
 
  45 
Nilsen, J., & Brinton, R. D. (2002). Impact of progestins on estrogen-induced 
neuroprotection: Synergy by progesterone and 19-norprogesterone and antagonism 
by medroxyprogesterone acetate. Endocrinology, 143(1), 205–212. 
 
Okojie, A. K., & Oyekunle, O. A. (2014). Depo-Provera effects on Wistar rat 
performance in the Y-maze. Metabolic Brain Disease, 29(2), 529–531. 
https://doi.org/10.1007/s11011-013-9460-9 
 
Paul, S., & Purdy, R. (1992). Neuroactive steroids. FASEB J, 6, 2311–2322. 
 
Prakapenka, A. V., Hiroi, R., Quihuis, A. M., Carson, C., Patel, S., Berns-Leone, C., … 
Bimonte-Nelson, H. A. (2018). Contrasting effects of individual versus combined 
estrogen and progestogen regimens as working memory load increases in middle-
aged ovariectomized rats: one plus one does not equal two. Neurobiology of Aging, 
64, 1–14. Retrieved from https://doi.org/10.1016/j.neurobiolaging.2017.11.015 
 
Rai, P., Rajaram, S., Goel, N., Ayalur Gopalakrishnan, R., Agarwal, R., & Mehta, S. 
(2009). Oral micronized progesterone for prevention of preterm birth. International 
Journal of Gynecology and Obstetrics, 104(1), 40–43. 
 
Rapp, S. R., Espeland, M. A., Shumaker, S. A., Henderson, V. W., Brunner, R. L., 
Manson, J. E., … Bowen, D. (2003). Effect of estrogen plus progestin on global 
cognitive function in postmenopausal women. JAMA : The Journal of the American 
Medical Association, 289(20), 2663–2672. https://doi.org/10.1001/jama.289.20.2663 
 
Reed, S. C., Evans, S. M., Bedi, G., Rubin, E., & Foltin, R. W. (2011). The effects of oral 
micronized progesterone on smoked cocaine self-administration in women. 
Hormones and Behavior, 59(2), 227–235. 
 
Ryan, N., & Rosner, A. (2001). Quality of life and costs associated with micronized 
progesterone and medroxyprogesterone acetate in hormone replacement therapy for 
nonhysterectomized, postmenopausal women. Clinical Therapeutics, 23(7), 1099–
1115. 
 
Shear, D. A., Galani, R., Hoffman, S. W., & Stein, D. G. (2002). Progesterone protects 
against necrotic damage and behavioral abnormalities caused by traumatic brain 
injury. Experimental Neurology, 178, 59–67. 
 
Sherwin, B. B., & Grigorova, M. (2011). Differential effects of estrogen and micronized 
progesterone or medroxyprogesterone acetate on cognition in postmenopausal 
women. Fertility and Sterility, 96(2), 399–403. 
 
Shumaker, S. a, Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., … 
Wactawski-Wende, J. (2003). Estrogen Plus Progestin and the Incidence of  
 
  46 
Dementia and Mild Cognitive Impairment in Postmenopausal Women. Jama, 
289(20), 2651–2662. https://doi.org/10.1001/jama.289.20.2651 
 
Sieghart, W., & Sperk, G. (2002). Subunit composition, distribution and function of 
GABA-A receptor subtypes. Current Topics in Medicinal Chemistry, 2, 795–816. 
 
Springer, L., Flaws, J., Sipes, I., & Hoyer, P. (1996). Follicular mechanisms associated 
with 4-vinylcyclohexene diepoxide-induced ovotoxicity in rats. Reproductive 
Toxicology, 10(2), 137–143. https://doi.org/10.1016/0890-6238(95)02056-X 
 
Stanczyk, F. Z. (2003). All progestins are not created equal. Steroids, 68, 879–890. 
 
Türkmen, Ş., Löfgren, M., Birzniece, V., Bäckström, T., & Johansson, I. M. (2006). 
Tolerance development to Morris water maze test impairments induced by acute 
allopregnanolone. Neuroscience, 139, 651–659. 
 
Wali, B., Ishrat, T., Won, S., Stein, D. G., & Sayeed, I. (2014). Progesterone in 
experimental permanent stroke: A dose-response and therapeutic time-window 
study. Brain AJournal of Neurology, 137, 486–502. 
 
Whiteman, M. K., Hillis, S. D., Jamieson, D. J., Morrow, B., Podgornik, M. N., Brett, K. 
M., & Marchbanks, P. A. (2008). Inpatient hysterectomy surveillance in the United 
States, 2000-2004. American Journal of Obstetrics and Gynecology, 198(1), 2000–
2004. https://doi.org/10.1016/j.ajog.2007.05.039 
 
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., 
Pouton, C. W., & Porter, C. J. H. (2013). Strategies to address low drug solubility in 
discovery and development. Pharmacological Reviews, 65, 315–499. 
46 
